

CURRICULUM VITAE



PERSONAL DETAILS

Surname : van Ingen
First name(s) : Jakobus (Jakko)
Date of birth : 14/06/1979
Place of birth : Kesteren
Nationality : Nederlandse (Dutch)

Private address : Vossenlaan 91, 6531 SG Nijmegen
Private telephone number : ++31-6-30825431
Private e-mail address : vaningen.jakko@gmail.com
Institute: Radboud University Medical Center
Work address : Department of Medical Microbiology (777), PO Box 9101, 6500 HB Nijmegen, the Netherlands
Work telephone number : +31-24-3614356
Work e-mail address : jakko.vaningen@radboudumc.nl

EDUCATION

Academic education

Discipline Medicine
Institution Radboud University Nijmegen, Nijmegen, Netherlands
Date 07/1997 – 05/2005
Degree(s) or diploma(s) M.D.

Discipline Medicine, PhD program
Institution Radboud University Nijmegen, Nijmegen, Netherlands
Date 09/2006 – 09/2009
Degree(s) or diploma(s) PhD

Relevant trainings and courses

Topic Clinical Training; Tuberculosis ward service
Institution Muhimbili University Dar es Salaam / Rubya Hospital, Tanzania
Date 2004, 4 months

Topic Denver TB course
Institution National Jewish Health, Denver, CO, USA
Date 2010, October

Topic Gaining expertise in mycobacterial infections
Institution ESCMID study group for mycobacterial infections (ESGMYC)
Date Paris, FR, 2013 May

Curriculum Vitae Jakko van Ingen

Language skills (1 = basic ; 2 = fair ; 3 = good ; 4 = excellent ; 5 = native speaker)

<i>Language</i>	<i>Passive</i>	<i>Spoken</i>	<i>Written</i>
Dutch	5	5	5
English	4	4	4
French	3	3	2
German	3	3	2

WORKING EXPERIENCE

Positions held

<i>Date</i>	02/2016 - now
<i>Location</i>	Nijmegen, Netherlands
<i>Company</i>	Radboud University Medical Centre; Medical Microbiology
<i>Position</i>	MD, PhD, consultant Clinical Microbiologist and Head of Mycobacteriology
<i>Date</i>	01/2011 – 01/2016
<i>Location</i>	Nijmegen, Netherlands
<i>Company</i>	Radboud University Medical Centre; Medical Microbiology
<i>Position</i>	MD, Resident in Clinical Microbiology (Supervisor: P.E. Verweij)
<i>Date</i>	08/2010 – 01/2011
<i>Location</i>	Denver, Colorado, United States of America
<i>Company</i>	National Jewish Health
<i>Position</i>	PhD, Research Associate (post-doc; Supervisors: C.L. Daley & L.B. Heifets)
<i>Date</i>	09/2006 – 09/2010
<i>Location</i>	Bilthoven / Nijmegen, Netherlands
<i>Company</i>	Mycobacteria Reference Unit, National Institute for Public Health and the Environment
<i>Position</i>	MD, PhD candidate (Supervisors: P.N.R. Dekhuijzen & D. van Soolingen)
<i>Date</i>	04/2005 - 09/2006
<i>Location</i>	Nijmegen, Netherlands
<i>Company</i>	Radboud University Nijmegen Medical Centre; Pulmonary Diseases
<i>Position</i>	MD (Supervisor: M.J. Boeree)

GUIDELINE COMMITTEE POSTS

Committee member “Laboratory diagnosis of mycobacterial diseases; Dutch national guideline” (Publ: 08/2015)

Committee member “Screening, Diagnosis and Treatment of nontuberculous mycobacterial disease in CF patients; international guideline” (Publ: 1/2016)

Committee member “Diagnosis and treatment of pulmonary nontuberculous mycobacteria disease” (American Thoracic Society / European Respiratory Society / Infectious Diseases Society of America / European Society for Clinical Microbiology and Infectious Diseases) (Exp. 09/2017)

MISCELLANEOUS

Supervisor of 2 PhD candidates; 3 PhD students graduated (W. Hoefsloot, 2013; S. Simons, 2015; B. Ferro, 2017)

Coordinator of NTM-net, a global NTM research initiative

Coordinator of national mycobacteriology quality control program in the Netherlands for “Stichting Kwaliteits Monitoring klinische Laboratoria (SKML)”

Chair of the Radboudumc infectious disease outbreak response team

Member of the European Society for Microbiology and Infectious Diseases (and ESGMYC working group)

Member of the European Respiratory Society

Member of the Dutch Society for Microbiology
Member of the American Society for Microbiology
Member of the European Society for Mycobacteriology

AWARDS

2008 Dutch Centre for Infectious Disease Control, Young Talent Award
2008 Nijmegen University Centre for Infectious Disease, Young Talent Award
2009 “cum laude”[with honors] PhD degree, Radboud University Nijmegen
2009 Laboratories for Infectious Diseases and Screening “man of the year”
2011 European Society for Mycobacteriology, Gertrud Meissner award for excellence in mycobacteriology
2015 Visiting Professor @ University of Tartu (Estonia) & University of Kiel / FZ Borstel (Germany)
2016 European Respiratory Society Research Award: Innovation in Non-Tuberculous Mycobacteria Science and Medicine

GRANTS

2016 Ministry of Health, Innovation Impulse: Veni grant for Research Group development: 250,000 Euro

PUBLICATIONS

139 publications in peer reviewed scientific journals.

H-index (16-07-2017): 28

1. [van Ingen J](#), Boeree MJ, Jansen M, Ullmann E, de Lange WCM, de Haas PEW, van Soolingen D. Pulmonary *Mycobacterium szulgai* infection and treatment in a patient receiving anti-tumor necrosis factor therapy. *Nat Clin Pract Rheumatol* 2007; 3: 414-9.
2. [van Ingen J](#), Boeree MJ, de Lange WC, Dekhuijzen PN, van Soolingen D. Impact of new American Thoracic Society diagnostic criteria on management of nontuberculous mycobacterial infection. *Am J Respir Crit Care Med* 2007; 176: 418.
3. [van Ingen J](#), Boeree MJ, Stals FS, Pitz CCM, Rooijmans-Rietjens JJCM, van der Zanden AGM, Dekhuijzen PNR, van Soolingen D. Clinical *Mycobacterium conspicuum* isolation from two immunocompetent patients in the Netherlands. *J Clin Microbiol* 2007; 45: 4075-6.
4. [van Ingen J](#), Boeree MJ, Dekhuijzen PNR, van Soolingen D. Clinical relevance of *Mycobacterium simiae* in pulmonary samples. *Eur Respir J* 2008; 31(1): 106-9.
5. [van Ingen J](#), Boeree MJ, de Lange WCM, de Haas PEW, Dekhuijzen PNR, van Soolingen D. Clinical relevance of *Mycobacterium szulgai* in the Netherlands. *Clin Infect Dis* 2008; 46(8): 1200-5.
6. [van Ingen J](#), Boeree MJ, de Lange WCM, Hoefsloot W, Bendien SA, Magis-Escurra C, Dekhuijzen PNR, van Soolingen D. *Mycobacterium xenopi* clinical relevance and determinants, the Netherlands. *Emerg Infect Dis* 2008; 14: 385-9.
7. Magis-Escurra C, Miedema JR, de Lange WCM, [van Ingen J](#), Dekhuijzen PNR, Boeree MJ. Een bijzondere populatie: tuberculose in Dekkerswald 2000-2005. *Ned Tijdschr Geneesk* 2008; 152(11): 622-6. [Dutch]
8. Hoefsloot W, Boeree MJ, [van Ingen J](#), Bendien S, Magis C, de Lange W, Dekhuijzen PN, van Soolingen D. The rising incidence and clinical relevance of *Mycobacterium malmoense*: a review of the literature. *Int J Tuberc Lung Dis* 2008; 12(9): 987-93.
9. [van Ingen J](#), Boeree MJ, Wright A, van der Laan T, Dekhuijzen PNR, van Soolingen D. Second-line drug resistance in multi-drug resistant tuberculosis cases of various origins in the Netherlands. *Int J Tuberc Lung Dis* 2008; 12 (11): 1295-9.
10. [van Ingen J](#), Boeree MJ, Dekhuijzen PNR, van Soolingen D. Mycobacterial disease in patients with rheumatic disease. *Nat Clin Pract Rheumatol* 2008; 4(12): 649-656. (solicited review)
11. Crump JA, [van Ingen J](#), Morrissey AB, Boeree MJ, Mavura DR, Swai B, Thielman NM, Bartlett JA, Grossman H, Maro VP, van Soolingen D. Invasive disease caused by nontuberculous mycobacteria in HIV-infected patients, Tanzania. *Emerg Infect Dis* 2009; 15(1): 53-55.
12. Al-Mahruqi SA, [van Ingen J](#), Al-Busaidy S, Boeree MJ, Al-Zadjali S, Patel A, Dekhuijzen PNR, and van Soolingen D. Clinical relevance of nontuberculous mycobacteria, Oman. *Emerg Infect Dis* 2009; 15(2): 292-4.
13. Hofmann-Thiel S, van Ingen J, Feldmann K, Turaev L, Uzakova GT, Murmusaeva G, van Soolingen D, Hoffmann H. Mechanisms of heteroresistance to isoniazid and rifampin of *Mycobacterium tuberculosis* in Tashkent, Uzbekistan. *Eur Respir J* 2009; 33(2): 368-74.
14. [van Ingen J](#), Boeree MJ, de Lange WCM, de Haas PEW, van der Zanden AGM, Mijs W, Rigouts L, Dekhuijzen PNR, van Soolingen D. *Mycobacterium noviomagense* sp. nov.; clinical relevance evaluated in 17 patients. *Int J Syst Evol Microbiol* 2009; 59(4): 845-9.

15. [van Ingen J](#), Al-Hajoj SA, Boeree MJ, Al-Rabiah F, Enaimi M, de Zwaan R, Tortoli E, Dekhuijzen PNR, van Soolingen D. *Mycobacterium riyadhense* sp. nov.; a non-tuberculous species identified as *Mycobacterium tuberculosis* complex by a commercial line-probe assay. *Int J Syst Evol Microbiol* 2009; 59(5): 1049-53.
16. [van Ingen J](#), Bendien SA, de Lange WCM, Hoefsloot W, Dekhuijzen PNR, Boeree MJ, van Soolingen D. Clinical relevance of nontuberculous mycobacteria isolated in the Nijmegen-Arnhem region, the Netherlands. *Thorax* 2009; 64(6): 502-6.
17. Tortoli E, Baruzzo S, Heijdra Y, Klenk H-P, Stefania Lauria, Mariottini A, [van Ingen J](#). *Mycobacterium insubricum* sp. nov. *Int J Syst Evol Microbiol* 2009; 59(6): 1518-23.
18. [van Ingen J](#), van der Laan T, Amaral L, Dekhuijzen R, Boeree MJ, van Soolingen D. In vitro activity of thioridazine against mycobacteria. *Int J Antimicrob Agents* 2009; 34(2):190-1.
19. Hoefsloot W, [van Ingen J](#), de Lange WCM, Dekhuijzen PNR, Boeree MJ, van Soolingen D. Clinical relevance of *Mycobacterium malmoense* isolation in the Netherlands. *Eur Respir J* 2009; 34(4): 926-31.
20. [van Ingen J](#), de Zwaan R, Dekhuijzen PNR, Boeree MJ, van Soolingen D. The Region of Difference 1 in nontuberculous *Mycobacterium* species adds a phylogenetic and taxonomical character. *J Bacteriol* 2009; 191(18): 5865-7.
21. [van Ingen J](#), Boeree MJ, Kösters K, Wieland A, Tortoli E, Dekhuijzen PNR, van Soolingen D. Proposal to elevate *Mycobacterium avium* complex ITS sequevar MAC-Q to *Mycobacterium vulneris* sp nov. *Int J Syst Evol Microbiol* 2009; 59(9): 2277-82.
22. [van Ingen J](#), Lindeboom JA, Hartwig NG, de Zwaan R, Tortoli E, Dekhuijzen PNR, Boeree MJ, van Soolingen D. *Mycobacterium mantenii* sp. nov.; A novel pathogenic slowly growing scotochromogenic species. *Int J Syst Evol Microbiol* 2009; 59(11): 2782-7.
23. [van Ingen J](#), Boeree M, Dekhuijzen R, van Soolingen D. Environmental sources of rapid growing nontuberculous mycobacteria causing disease in humans. *Clin Microbiol Infect* 2009; 15(10): 888-93.
24. Swart RM, [van Ingen J](#), van Soolingen D, Slingerland R, Hendriks WDH, den Hollander JG. Nontuberculous *Mycobacterium* infection and tumor necrosis factor- α antagonists. *Emerg Infect Dis* 2009; 15(10): 1700-1.
25. [van Ingen J](#), de Zwaan R, Dekhuijzen R, Boeree M, van Soolingen D. Clinical relevance of *Mycobacterium chelonae-abscessus* group isolation in 95 patients. *J Infect* 2009; 59(5): 324-31.
26. [van Ingen J](#), de Zwaan CC, Enaimi M, Dekhuijzen PNR, Boeree MJ, van Soolingen D. Re-analysis of 178 previously unidentifiable *Mycobacterium* isolates in the Netherlands, from the 1999-2007 period. *Clin Microbiol Infect* 2010; 16(9):1470-4.
27. [van Ingen J](#), Verhagen AFTM, Dekhuijzen PNR, van Soolingen D, Magis-Escurra C, Boeree MJ, de Lange WCM. Surgical treatment of nontuberculous mycobacterial lung disease: Strike in time. *Int J Tuberc Lung Dis* 2010; 14(1): 99-105.
28. [van Ingen J](#), Looijmans F, Mirck P, Dekhuijzen R, Boeree MJ, van Soolingen D. Otomastoiditis caused by *Mycobacterium abscessus*, the Netherlands. *Emerg Infect Dis* 2010; 16(1): 166-168.
29. [van Ingen J](#), van der Laan T, Dekhuijzen PNR, Boeree MJ, van Soolingen D. *In vitro* drug susceptibility of 2275 clinical nontuberculous *Mycobacterium* isolates of 49 species in the Netherlands. *Int J Antimicrob Agents* 2010; 35(2): 169-73.
30. [van Ingen J](#), Hoefsloot W, de Lange WCM, Magis-Escurra C, Dekhuijzen PNR, Boeree MJ, van Soolingen D. Nontuberculeuze mycobacteriën: klinisch relevant. *Ned Tijdschr Geneesk* 2010;154: A1178. [Dutch]
31. [van Ingen J](#), Wisselink HJ, van Solt-Smits CB, Boeree MJ, van Soolingen D. Isolation of mycobacteria other than *Mycobacterium avium* from porcine lymph nodes. *Vet Microbiol* 2010; 144(1-2): 250-3.
32. Wellenberg GJ, de Haas PEW, van Ingen J, van Soolingen D, Visser IJR. Multiple strains of *Mycobacterium avium* subspecies *hominissuis* infections associated with aborted fetuses and wasting in pigs. *Vet Rec* 2010; 167(12): 451-4.
33. [van Ingen J](#), Hoefsloot W, Dekhuijzen PNR, Boeree MJ, van Soolingen D. The changing pattern of clinical *Mycobacterium avium* isolation in the Netherlands. *Int J Tuberc Lung Dis* 2010; 14(9): 1176-80.
34. Verweij KE, Kamerik AR, [van Ingen J](#), van Dijk J, Sikwangala P, Thuma P, Nouwen JL, van Soolingen D. Application of modern microbiological diagnostic methods for Tuberculosis in Macha, Zambia. *Int J Tuberc Lung Dis* 2010; 14(9): 1127-31.
35. De Groot PHS, [van Ingen J](#), de Zwaan R, Mulder A, Boeree MJ, van Soolingen D. Disseminated *Mycobacterium avium* subsp. *avium* infection in a cat, the Netherlands. *Vet Microbiol* 2010; 144(3-4):527-9.
36. [van Ingen J](#), Simons S, de Zwaan R, van der Laan T, Kamst-van Agterveld M, Boeree MJ, van Soolingen D. Comparative study on genotypic and phenotypic second line drug resistance testing of *Mycobacterium tuberculosis* complex isolates. *J Clin Microbiol* 2010; 48(8): 2749-53.
37. [van Ingen J](#), Blaak H, de Beer J, de Roda Husman AM, van Soolingen D. Rapidly growing nontuberculous mycobacteria cultured from home tap and shower water. *Appl Environ Microbiol* 2010; 76(17): 6017-9.
38. [van Ingen J](#), Tortoli E, Selvarangan R, Coyle MB, Crump JA, Morrissey AB, Dekhuijzen PNR, Boeree MJ, van Soolingen D. *Mycobacterium sherrisii* sp. nov.; a slow-growing non-chromogenic species. *Int J Syst Evol Microbiol* 2011; 61: 1293-8.
39. Al-Hajoj SAM, Akkerman O, Parwati I, al-Gamdi S, Rahim Z, van Soolingen D, [van Ingen J](#), Supply P, van der Zanden AGM. Micro-evolution of *Mycobacterium tuberculosis* in a tuberculosis patient. *J Clin Microbiol* 2010; 48(10): 3813-6.
40. Fabre M, Hauck Y, Soler C, Koeck J-L, [van Ingen J](#), van Soolingen D, Vergnaud G, Pourcel C. Molecular characteristics of “*Mycobacterium canettii*” the smooth *Mycobacterium tuberculosis* bacilli. *Infect Gen Evol* 2010; 10(8): 1165-73.
41. van Soolingen D, Hernandez Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, [van Ingen J](#), Boeree MJ. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. *PLoS One* 2010; 5(9). pii: e12640.
42. Simons S, [van Ingen J](#), Hseuh PR, Hung NV, Dekhuijzen PNR, Boeree MJ, van Soolingen D. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. *Emerg Infect Dis* 2011; 17(3): 343-9.
43. Majoor C, Magis-Escurra C, [van Ingen J](#), Boeree MJ, van Soolingen D. Epidemiology of *Mycobacterium bovis* disease in humans, the Netherlands. *Emerg Infect Dis* 2011; 17(3): 457-63.

44. [van Ingen J](#), Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ. Why do we use 600mg of rifampicin in tuberculosis treatment? *Clin Infect Dis* 2011; 52(9): e194-9.
45. [van Ingen J](#). Strategies to improve outcome of drug treatment for *Mycobacterium abscessus* pulmonary disease. *Clin Infect Dis* 2011; 52(10): 1281-2.
46. [van Ingen J](#), van Soolingen D. Cervicofacial lymphadenitis caused by nontuberculous mycobacteria; host, environmental or bacterial factors? *Int J Pediatr Otorhinolaryngol* 2011; 75(5): 722-23.
47. [van Ingen J](#). The broad-spectrum antimycobacterial activities of phenothiazines, in vitro: Somewhere in all of this there may be patentable potentials. *Recent Pat Antiinfect Drug Discov* 2011; 6(2): 104-9.
48. [van Ingen J](#), Aarnoutse R, de Vries G, Boeree MJ, van Soolingen D. Low-level rifampicin resistant *Mycobacterium tuberculosis* strains raise a new therapeutic challenge. *Int J Tuberc Lung Dis* 2011; 15(7): 990-2.
49. Bowles EC, Freyee B, [van Ingen J](#), Mulder B, Boeree MJ, van Soolingen D. The Xpert MTB/RIF, a novel automated PCR-based tool for the diagnosis of tuberculosis. *Int J Tuberc Lung Dis* 2011; 15(7): 988-9.
50. van den Boogaard J, Semvua H, [van Ingen J](#), Mwaigwisya S, van der Laan T, van Soolingen D, Kibiki G, Boeree M, Aarnoutse R. Low rate of fluoroquinolone resistance in *Mycobacterium tuberculosis* isolates from northern Tanzania. *J Antimicrob Chemother* 2011; 66: 1810-1814.
51. [van Ingen J](#), de Lange WCM, Boeree MJ, Iseman MD, Daley CL, Heifets LB, Böttger EC, van Soolingen D. XDR tuberculosis. *Lancet Infect Dis* 2011; 11(8): 585.
52. Hartwig NG, Warris A, van de Vosse, van der Zanden AGM, Schölin-Casonato T, [van Ingen J](#), van Hest R. 'Mycobacterium *tuberculosis* complex' infection in two immunocompromised children: importance of molecular tools in culture-negative mycobacterial disease. *J Clin Microbiol* 2011; 49(12): 4409-11.
53. [van Ingen J](#), Boeree MJ, van Soolingen D, Iseman MD, Heifets LB, Daley CL. Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated? *Infect Gen Evol* 2012; 12(4): 832-7.
54. [van Ingen J](#), Totten SE, Heifets LB, Boeree MJ, Daley CL. Drug susceptibility testing and pharmacokinetics question current treatment regimens in *Mycobacterium simiae* complex disease. *Int J Antimicrob Agents* 2012; 39(2): 173-6.
55. Simons SO, [van Ingen J](#), van der Laan T, Mulder A, Dekhuijzen PN, Boeree MJ, van Soolingen D. Validation of *pncA* gene sequencing in combination with the MGIT method to test susceptibility of *Mycobacterium tuberculosis* to pyrazinamide. *J Clin Microbiol* 2012; 50(2): 428-34.
56. [van Ingen J](#), Rahim Z, Mulder A, Boeree MJ, Simeone R, Brosch R, van Soolingen D. Characterization of *Mycobacterium orygis* as *M. tuberculosis* complex subspecies. *Emerg Infect Dis* 2012; 18(4): 653-5.
57. Hoefsloot W, [van Ingen J](#), Peters E, Magis-Escurra C, Dekhuijzen R, Boeree M, van Soolingen D. *Mycobacterium genavense* in the Netherlands: an opportunistic pathogen in HIV and non-HIV immunocompromised patients. An observational study in 14 cases. *Clin Microbiol Infect* 2013; 19(5): 432-7.
58. Greif G, Coitinho C, Rivas C, [van Ingen J](#), Robello C. Molecular analysis of isoniazid-resistant *Mycobacterium tuberculosis* isolates in Uruguay. *Int J Tuberc Lung Dis* 2012; 16(7):947-9.
59. [van Ingen J](#), Boeree M, van Soolingen D, Mouton J. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. *Drug Resist Updat* 2012; 15(3): 149-61.
60. Houben D, Demangel C, [van Ingen J](#), Perez J, Baldeón L, Abdallah AM, Caleechurn L, Bottai D, van Zon M, de Punder K, van der Laan T, Kant A, Bossers-de Vries R, Willemsen P, Bitter W, van Soolingen D, Brosch R, van der Wel N, Peters PJ. ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria. *Cell Microbiol* 2012; 14: 1287-98.
61. Verregghen M, Heijerman H, Reijers M, [van Ingen J](#), van der Ent CK. Risk factors for *Mycobacterium abscessus* infection in cystic fibrosis patients; a case-control study. *J Cyst Fibros* 2012; 11: 340-3.
62. [van Ingen J](#), Hoefsloot W, Buijtsels PCAM, Dekhuijzen PNR, Supply P, Boeree MJ, van Soolingen D. Characterization of an *M. chimaera* variant. *J Med Microbiol* 2012; 61(9):1234-9.
63. [van Ingen J](#), Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse R, Heifets LB, Peloquin CA, Daley CL. The pharmacokinetics and pharmacodynamics of pulmonary *Mycobacterium avium* complex disease treatment. *Am J Respir Crit Care Med* 2012; 186(6): 559-65.
64. Coitinho C, Greif G, Robello C, [van Ingen J](#), Rivas C. Identification of *Mycobacterium tuberculosis* complex by polymerase chain reaction of Exact Tandem Repeat-D fragment from mycobacterial cultures. *Int J Mycobacteriol* 2012; 1(3):146-8.
65. Van der Zanden RJC, Magis-Escurra C, de Lange WC, Hoefsloot W, Boeree MJ, [van Ingen J](#), van Soolingen D. Hypersensitivity pneumonitis caused by *Mycobacterium avium* subsp. *hominissuis* in a hot tub, as proven by IS1245 RFLP and rep-PCR typing. *Int J Mycobacteriol* 2012; 1(3): 152-4.
66. van Soolingen D, [van Ingen J](#). On the road to unravelling the aetiology of non-tuberculous mycobacterial disease (Editorial). *Int J Tuberc Lung Dis* 2012; 16(10):1279.
67. [van Ingen J](#), Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL. In Vitro Synergy Between Clofazimine And Amikacin in Nontuberculous Mycobacterial Disease. *Antimicrob Agents Chemother* 2012; 56(12): 6324-7.
68. Hoefsloot W, Boeree MJ, van Nieuwkoop C, Bernards AT, Savelkoul PH, [van Ingen J](#), van Soolingen D. No human transmission of *Mycobacterium malmoense* in a perfect storm setting. *Eur Respir J* 2012; 40(6): 1576-8.
69. Simons SO, Mulder A, [van Ingen J](#), Boeree MJ, van Soolingen D. Role of *rpsA* gene sequencing in diagnosis of pyrazinamide resistance. *J Clin Microbiol* 2013; 51(1):382.
70. [van Ingen J](#), Hilt N, Bosboom R. Education of phlebotomy teams improves blood volume in blood culture bottles. *J Clin Microbiol* 2013; 51(3): 1020-1.
71. [van Ingen J](#). Diagnosis of nontuberculous mycobacterial disease. *Semin Respir Crit Care Med* 2013; 34(1): 103-9.
72. [van Ingen J](#), Anthony RM. Re-think first line tuberculosis treatment. *Eur Respir J* 2013; 41(2): 488-9.
73. Al-Hajoj S, Varghese B, [van Ingen J](#), van Soolingen D. *Mycobacterium riyadhense* overlooked: we can only find what we are looking for. *J Infect Dev Ctries* 2013; 7(3): 293-294.
74. [van Ingen J](#), Brosch R, van Soolingen D. Characterization of *Mycobacterium orygis*. *Emerg Infect Dis* 2013; 19(3): 521-2.

75. Shojaei H, Daley CL, Gitti Z, Hashemi A, Heidarieh P, Moore E, Naser AD, Osterhout J, Russo C, van Ingen J, Tortoli E. *Mycobacterium iranicum* sp. nov., a rapidly growing scotochromogenic species isolated from clinical specimens in three different continents. *Int J Syst Evol Microbiol* 2013; 63(4): 1383-9.
76. van Ingen J, Bunnik R, Sturm PDJ. Female with long-standing cough. *Photo Quiz. J Clin Microbiol* 2013; 51(4): 1065, 1353.
77. de Beer JL, van Ingen J, de Vries G, Erkens C, Sebek M, Mulder A, Sloot R, van den Brandt AM, Enaimi M, Kremer K, Supply P, van Soolingen D. Comparative study of IS6110 RFLP and VNTR typing of *Mycobacterium tuberculosis* in the Netherlands, based on a five year nationwide survey. *J Clin Microbiol* 2013; 51(4): 1193-8.
78. Simons SO, Kristiansen JE, Hajos G, van der Laan T, Molnár J, Boeree MJ, van Ingen J, Christensen JB, Viveiros M, Riedl Z, Amaral L, van Soolingen D. Activity of the efflux pump inhibitor SILA 421 against drug-resistant tuberculosis. *Int J Antimicrob Agents* 2013; 41(5): 488-9.
79. Jankovic M, Samarzija M, Sabol I, Jakopovic M, Katalinic-Jankovic V, Zmak L, Ticac B, Marusic A, Obrovac M, van Ingen J. Geographical distribution and clinical relevance of non-tuberculous mycobacteria in Croatia. *Int J Tuberc Lung Dis* 2013; 17(6): 836-41.
80. Hoefsloot W, van Ingen J, Magis-Escurra C, Reijers MH, van Soolingen D, Dekhuijzen RP, Boeree MJ. Prevalence Of Nontuberculous Mycobacteria In COPD Patients With Exacerbations. *J Infect* 2013; 66(6): 542-5.
81. van Ingen J, Hoefsloot W, Mouton JW, Boeree MJ, van Soolingen D. Synergistic activity of rifampicin and ethambutol against slow growing nontuberculous mycobacteria is currently of questionable clinical significance. *Int J Antimicrob Agents* 2013; 42(1): 80-2.
82. Sloot R, Borgdorff MW, de Beer JL, van Ingen J, Supply P, van Soolingen D. Clustering of tuberculosis cases based on Variable Number of Tandem Repeat typing in relation to the population structure of *Mycobacterium tuberculosis* in the Netherlands. *J Clin Microbiol* 2013; 51(7): 2427-31.
83. Magis-Escurra C, Alffenaar JW, Hoefnagels I, Dekhuijzen PN, Boeree MJ, van Ingen J, Aarnoutse RE. Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. *Int J Antimicrob Agents*. 2013; 42(3): 256-61.
84. Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V, Chimara E, Churchyard G, Cias R, Dasa R, Daley CL, Dekhuijzen PN, Domingo D, Drobniowski F, Esteban J, Fauville-Dufaux M, Folkvardsen DB, Gibbons N, Gómez-Mampaso E, Gonzalez R, Hoffmann H, Hsueh PR, Indra A, Jagielski T, Jamieson F, Jankovic M, Jong E, Keane J, Koh WJ, Lange B, Leao S, Macedo R, Mannsåker T, Marras TK, Maugein J, Milburn HJ, Mlinkó T, Morcillo N, Morimoto K, Papaventsis D, Palenque E, Paez-Peña M, Piersimoni C, Polanová M, Rastogi N, Richter E, Ruiz-Serrano MJ, Silva A, da Silva MP, Simsek H, van Soolingen D, Szabó N, Thomson R, Fernandez MT, Tortoli E, Totten SE, Tyrrell G, Vasankari T, Villar M, Walkiewicz R, Winthrop K, Wagner D; for NTM-NET (www.ntm-net.org). The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: A NTM-NET collaborative study. *Eur Respir J*. 2013; 42(6):1604-13.
85. van Ingen J, Ferro BE, Hoefsloot W, Boeree MJ, van Soolingen D. Treatment of nontuberculous mycobacterial lung disease in HIV-negative patients – the evidence. *Expert Rev Anti Infect Ther* 2013; 11(10): 1065-77.
86. Kolwijck E, Friedrich S, Karinja M, van Ingen J, Warren R, Diacon A. Early stationary phase culture supernatant accelerates growth of sputum cultures collected after initiation of anti-tuberculosis treatment. *Clin Microbiol Infect* 2014; 20(7): O418-20.
87. Jagielski T, van Ingen J, Rastogi N, Dziadek J, Mazur P, Bielecki JE. Current methods in the molecular typing of *Mycobacterium tuberculosis* and other mycobacteria. *Biomed Res Int* 2014; 2014: 645802.
88. Jagielski T, van Ingen J, Rastogi N, Dziadek J. Recent Developments in Mycobacteriology: A Clinical and Diagnostic Perspective. *Biomed Res Int* 2014; 2014: 813185.
89. De Beer J, Kodmon C, van der Werf M, van Ingen J, van Soolingen D; ECDC MDR-TB molecular surveillance project participants. Molecular surveillance of multi- and extensively drug-resistant tuberculosis transmission in the European Union from 2003 to 2011. *Euro Surveill*. 2014; 19(11). pii: 20742.
90. De Beer JL, Akkerman O, Schürch A, Mulder A, van der Werf T, van der Zanden A, van Ingen J, van Soolingen D. Optimization of standard in-house 24-locus Variable Number of Tandem Repeat typing for *Mycobacterium tuberculosis* and its direct application to clinical material. *J Clin Microbiol* 2014; 52(5): 1338-42.
91. de Beer JL, Ködmön C, van Ingen J, Supply P, van Soolingen D; Global Network for the Molecular Surveillance of Tuberculosis 2010. Second worldwide proficiency study on variable number of tandem repeats typing of *Mycobacterium tuberculosis* complex. *Int J Tuberc Lung Dis* 2014; 18(5): 594-600.
92. de Zwaan R, van Ingen J, van Soolingen D. Utility of *rpoB* gene sequencing for identification of nontuberculous mycobacteria in the Netherlands. *J Clin Microbiol* 2014; 52(7): 2544-51.
93. Simons S, van der Laan T, Mulder A, van Ingen J, Rigouts L, Dekhuijzen R, Boeree M, van Soolingen D. Rapid diagnosis of pyrazinamide-resistant MDR-TB using a molecular-based diagnostic algorithm. *Clin Microbiol Infect* 2014; 20(10): 1015-20.
94. Ricketts WM, O'Shaughnessy TC, van Ingen J. Human-to-human transmission of *Mycobacterium kansasii* or victims of a shared source? *Eur Respir J* 2014; 44(4): 1085-7.
95. Bax HI, van Ingen J, Dwarkasing RS, Verbon A. Lipotourism; not without risks. *Ned Tijdschr Geneesk*. 2014; 158: A7926.
96. van Ingen J, Kuijper EJ. Drug susceptibility testing of nontuberculous mycobacteria. *Future Microbiology* 2014; 9: 1095-110.
97. van Ingen J, van der Lee HA, Rijs T, Zoll J, Leenstra T, Melchers WJ, Verweij PE. Azole, polyene and echinocandin MIC distributions of wild type, TR34/L98H and TR46/Y121F/T289A *Aspergillus fumigatus* isolates in the Netherlands. *J Antimicrob Chemother* 2015; 70(1): 178-81.
98. Ferro BE, van Ingen J, Wattenberg M, van Soolingen D, Mouton JW. Time-kill kinetics of antibiotics active against rapidly growing mycobacteria. *J Antimicrob Chemother* 2015; 70(3): 811-7.
99. Neerinx A, Mandon J, van Ingen J, Arslanov D, Mouton J, Harren F, Merkus P, Cristescu S. Real-time monitoring of hydrogen cyanide (HCN) and ammonia (NH₃) emitted by *Pseudomonas aeruginosa*. *J Breath Res* 2015; 9(2): 027102.

100. [van Ingen J](#). Microbiological diagnosis of pulmonary disease caused by nontuberculous mycobacteria. *Clin Chest Med* 2015; 36(1): 43-54.
101. Lopez-Varela E, Garcia-Basteiro AL, Santiago B, Wagner D, [van Ingen J](#), Kampmann B. Non-tuberculous mycobacteria in children: muddying the waters of tuberculosis diagnosis. *Lancet Respir Med* 2015; 3(3): 244-56.
102. [van Ingen J](#). Treatment of pulmonary disease caused by non-tuberculous mycobacteria. *Lancet Respir Med* 2015; 3(3): 179-80.
103. Hase I, Morimoto K, Sakagami T, Kazumi Y, Ishii Y, [van Ingen J](#). Disseminated *Mycobacterium gordonae* and *Mycobacterium mantenii* infection with elevated anti-IFN- γ neutralizing autoantibodies. *J Infect Chemother* 2015; 21(6): 468-72.
104. Trapman M, [van Ingen J](#), Keijman J, Swanink CM. Urinary tract infection caused by a capnophilic *Proteus mirabilis* strain. *J Clin Microbiol* 2015; 53(6): 1959-60.
105. [van Ingen J](#), van der Lee HA, Rijs AJ, Snelders E, Melchers WJ, Verweij PE. High-level pan-azole-resistant aspergillosis. *J Clin Microbiol* 2015; 53(7): 2343-5.
106. Boeree MJ, Diacon AH, Dawson R, Narunsky K, Du Bois J, Venter A, Phillips PPJ, Gillespie SH, Mc Hugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, [van Ingen J](#), Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE. A dose ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. *Am J Respir Crit Care Med* 2015; 191(9): 1058-65.
107. Simons SO, van der Laan T, de Zwaan R, Kamst M, [van Ingen J](#), Dekhuijzen PN, Boeree MJ, van Soolingen D. Molecular drug susceptibility testing in the Netherlands: performance of the MTBDRplus and MTBDRsl assays. *Int J Tuberc Lung Dis* 2015; 19(7): 828-33.
108. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, [van Ingen J](#), Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE. A Step toward an optimized rifampin dose completed. *Am J Respir Crit Care Med* 2015; 192(4): 525-6.
109. Ferro BE, [van Ingen J](#), Wattenberg M, van Soolingen D, Mouton JW. Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. *J Antimicrob Chemother* 2015; 70(10): 2838-43.
110. Kohler P, Kuster SP, Bloemberg G, Schulthess B, Frank M, Tanner FC, Rössle M, Böni C, Falk V, Wilhelm MJ, Sommerstein R, Achermann Y, Ten Oever J, Debast SB, Wolfhagen MJ, Brandon Bravo Bruinsma GJ, Vos MC, Bogers A, Serr A, Beyersdorf F, Sax H, Böttger EC, Weber R, [van Ingen J](#)*, Wagner D*, Hasse B*. Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated *Mycobacterium chimaera* infections subsequent to open heart surgery. *Eur Heart J* 2015; 36(40): 2745-53.
111. Coitinho C, Greif G, [van Ingen J](#), Laserra P, Robello C, Rivas C. First case of *Mycobacterium heckeshornense* cavitary lung disease in the Latin America and Caribbean region. *New Microbes New Infect.* 2015; 9: 63-5.
112. Ichikawa K, [van Ingen J](#), Koh WJ, Wagner D, Salfinger M, Inagaki T, Uchiya KI, Nakagawa T, Ogawa K, Yamada K, Yagi T. Genetic diversity of clinical *Mycobacterium avium* subsp. *hominissuis* and *Mycobacterium intracellulare* isolates causing pulmonary diseases recovered from different geographical regions. *Infect Genet Evol* 2015; 36 (12): 250-5.
113. Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann J-L, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, [van Ingen J](#), Wallace RJ, Winthrop KL, Marshall BC, Haworth CS. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. *Thorax* 2016; 71(Suppl 1): 1-22.
114. Neerinx A, Geurts B, Habets M-F, Booij J, van Loon J, Jansen J, Buydens L, [van Ingen J](#), Mouton J, Harren F, Wevers R, Merkus P, Cristescu S, Kluijtmans L. Identification of *Pseudomonas aeruginosa* and *Aspergillus fumigatus* mono- and co-cultures based on volatile biomarker combinations. *J Breath Res* 2016; 10(1): 016002.
115. Ferro BE, Meletiadi J, Wattenberg M, de Jong A, van Soolingen D, Mouton JW, [van Ingen J](#). Clofazimine prevents the regrowth of *Mycobacterium abscessus* and *Mycobacterium avium* type strains exposed to amikacin and clarithromycin. *Antimicrob Agents Chemother* 2016; 60(2): 1097-105.
116. Ferro BE, Srivastava S, Deshpande D, Sherman CM, Pasipanodya JG, van Soolingen D, Mouton JW, [van Ingen J](#), Gumbo T. Amikacin pharmacokinetics/pharmacodynamics in a novel hollow fiber *Mycobacterium abscessus* disease model. *Antimicrob Agents Chemother* 2016; 60(3): 1242-8.
117. Slaats MH, Hoefsloot W, Magis-Escurra C, Boeree MJ, Wattenberg M, Kuipers S, [van Ingen J](#). Regimens for nontuberculous mycobacterial lung disease lack early bactericidal activity. *Eur Respir J* 2016; 47(3): 1000-2.
118. Becker KL, [van Ingen J](#), Ten Oever J, Merkus PJ, Ferwerda G, Netea MG, Magis-Escurra C, Reijers MH, van de Veerdonk FL. Deficient interleukin-17 production in response to *Mycobacterium abscessus* in cystic fibrosis. *Eur Respir J* 2016; 47(3): 990-3.
119. Bakula Z, Modrzejewska M, Safianowska A, [van Ingen J](#), Proboszcz M, Bielecki J, Jagielski T. Proposal of a new method for subtyping of *Mycobacterium kansasii* based upon PCR restriction enzyme analysis of the *tuf* gene. *Diagn Microbiol Infect Dis* 2016; 84(4):318-21.
120. Jagielski T, Minias A, [van Ingen J](#), Rastogi N, Brzostek A, Zaczek A, Dziadek J. Molecular epidemiology of *Mycobacterium tuberculosis* and other mycobacteria: methodological and clinical aspects. *Clin Microbiol Rev* 2016; 29(2):239-90.
121. Ferro BE, Srivastava S, Deshpande D, Pasipanodya J, van Soolingen D, Mouton JW, [van Ingen J](#), Gumbo T. Tigecycline is highly efficacious in *Mycobacterium abscessus* pulmonary disease. *Antimicrob Agents Chemother* 2016; 60(5): 2895-900.
122. Ferro BE, Srivastava S, Deshpande D, Pasipanodya J, van Soolingen D, Mouton JW, [van Ingen J](#), Gumbo T. Moxifloxacin's limited efficacy in the hollow-fiber model of *Mycobacterium abscessus* disease. *Antimicrob Agents Chemother* 2016; 60(6): 3779-85.

123. Neerinx A, Linders YA, Vermeulen L, Belderbos RA, Mandon J, van Mastrigt E, Pijnenburg MW, van Ingen J, Mouton JW, Kluijtmans LA, Wevers RA, Harren FJ, Cristescu SM, Merkus PJ. Hydrogen cyanide (HCN) emission in the lung by *Staphylococcus aureus*. *Eur Respir J* 2016; 48(2): 577-9.
124. Strapagiel D, Borówka P, Marciniak B, Bakula Z, van Ingen J, Safianowska A, Brzostek A, Dziadek J, Jagielski T. Draft genome sequences of *Mycobacterium kansasii* strains 1010001454, 1010001458, 1010001468, 1010001493, 1010001495 and 1010001469, isolated from environmental sources. *Genome Announcements* 2016; 4(3): e00456-16.
125. van Eck K, Faro D, Wattenberg M, de Jong A, Kuiper S, van Ingen J. MALDI-TOF fails to identify nontuberculous mycobacteria directly from primary liquid cultures of respiratory samples. *J Clin Microbiol* 2016; 54(7): 1915-7.
126. Jankovic M, Sabol I, Zmak L, Katalinic-Jankovic V, Jakopovic M, Obrovac M, Ticac B, Kardum-Bulat L, Popovic-Grlc S, Marekovic I, Samarzija M, van Ingen J. Microbiologic criteria in nontuberculous mycobacterial pulmonary disease, a tool for diagnosis and epidemiology. *Int J Tuberc Lung Dis* 2016; 20(7): 934-40.
127. Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T. Failure of the amikacin, cefoxitin, and clarithromycin combination regimen for pulmonary *Mycobacterium abscessus*. *Antimicrob Agents Chemother* 2016; 60(10): 6374-6.
128. Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, Verma D, Hill E, Drijkoningen J, Gilligan P, Esther CR, Noone PG, Giddings O, Bell SC, Thomson R, Wainwright CE, Coulter C, Pandey S, Wood ME, Stockwell RE, Ramsay KA, Sherrard LJ, Kidd TJ, Jabbour N, Johnson GR, Knibbs LD, Morawska L, Sly PD, Jones A, Bilton D, Laurenson I, Ruddy M, Bourke S, Bowler IC, Chapman SJ, Clayton A, Cullen M, Dempsey O, Denton M, Desai M, Drew RJ, Edenborough F, Evans J, Folb J, Daniels T, Humphrey H, Isalska B, Jensen-Fangel S, Jönsson B, Jones AM, Katzenstein TL, Lillebaek T, MacGregor G, Mayell S, Millar M, Modha D, Nash EF, O'Brien C, O'Brien D, Ohri C, Pao CS, Peckham D, Perrin F, Perry A, Pressler T, Prtak L, Qvist T, Robb A, Rodgers H, Schaffer K, Shafi N, van Ingen J, Walshaw M, Watson D, West N, Whitehouse J, Haworth CS, Harris SR, Ordway D, Parkhill J, Floto RA. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. *Science* 2016; 354(6313): 751-7.
129. Andre E, Goeminne L, Cabibbe AM, Beckert P, Kabamba Mukadi B, Mathys V, Gagneux S, Niemann S, van Ingen J, Cambau E. Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. *Clin Microbiol Infect* 2017; 23(3): 167-172.
130. López-Varela E, L Garcia-Basteiro A, Augusto OJ, Fraile O, Bulo H, Ira T, Gondo K, van Ingen J, Naniche D, Sacarlal J, Alonso PL. High rates of non-tuberculous mycobacteria Isolation in Mozambican children with presumptive tuberculosis. *PLoS One* 2017; 12(1): e0169757.
131. Becker K, Arts P, Jaeger M, Plantinga T, Gilissen C, van Laarhoven A, van Ingen J, Veltman J, Joosten L, Hoischen A, Netea M, Iseman M, Chan ED, van de Veerdonk F. MST1R mutation as a genetic cause of Lady Windermere syndrome. *Eur Respir J* 2017; 49(1) pii: 1601478.
132. van Ingen J, Wagner D, Gallagher J, Morimoto K, Lange C, Haworth CS, Floto RA, Adjemian J, Prevots DR, Griffith DE. Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases. *Eur Respir J* 2017; 49(2) pii: 1601855.
133. Jagielski T; Partnership to Fight Against TB in Central and Eastern Europe (FATE). FATE: the new partnership to Fight Against TB in Central and Eastern Europe. *Lancet Infect Dis* 2017; 17: 363.
134. Mooren VHJF, Bleeker MWP, van Ingen J, Hermans MHA, Wever PC. Disseminated *Mycobacterium abscessus* infection in a peritoneal dialysis patient. *ID Cases* 2017; 9: 6-7.
135. Borówka P, Lach J, Bakula Z, van Ingen J, Safianowska A, Brzostek A, Dziadek J, Strapagiel D, Jagielski T. Draft genome sequences of *Mycobacterium kansasii* clinical strains. *Genome Announc* 2017; 5: e00406-17.
136. Hase I, Morimoto K, Sakagami T, Ishii Y, van Ingen J. Ethnicity and species determine the manifestations of anti-interferon-gamma autoantibody-associated nontuberculous mycobacterial disease. *Diagn Microbiol Infect Dis* 2017, May 18th, Epub ahead of print.
137. Ruth MM, Sangen JJN, Wertheim HFL, van Ingen J. Nifurtimox is ineffective against drug-resistant mycobacteria. *Antimicrob Agents Chemother* 2017, June 28th Epub ahead of print.
138. van Ingen J, Kohl TA, Kranzer K, Hasse B, Keller PM, Katarzyna Szafrńska A, Hillemann D, Chand M, Schreiber PW, Sommerstein R, Berger C, Genoni M, Rüegg C, Troillet N, Widmer AF, Becker SL, Herrmann M, Eckmanns T, Haller S, Höller C, Debast SB, Wolfhagen MJ, Hopman J, Kluytmans J, Langelaar M, Notermans DW, Ten Oever J, van den Barselaar P, Vonk ABA, Vos MC, Ahmed N, Brown T, Crook D, Lamagni T, Phin N, Smith EG, Zambon M, Serr A, Götting T, Ebner W, Thürmer A, Utpatel C, Spröer C, Bunk B, Nübel U, Bloemberg GV, Böttger EC, Niemann S, Wagner D, Sax H. Global outbreak of severe *Mycobacterium chimaera* disease after cardiac surgery: a molecular epidemiological study. *Lancet Infect Dis*. 2017 Jul 12, Epub ahead of print.
139. Adekambi T, Sassi M, van Ingen J, Drancourt M. Reinstating *Mycobacterium massiliense* and *Mycobacterium bolletii* as species of the *Mycobacterium abscessus* complex. *Int J Syst Evol Microbiol* 2017; Accepted.
140. Zweijpfenning S, Kops S, Magis-Escurra C, Boeree MJ, van Ingen J, Hoefsloot W. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort. *Resp Med* 2017, accepted for publication.

Book chapters:

1. J. van Ingen & D. van Soolingen. NTM infections. Nelson's textbook of pediatrics, 19th Edition. 2010.
2. J. van Ingen & D. van Soolingen. Molecular typing of nontuberculous mycobacteria. In: Molecular Typing in Bacterial Infections. De Filipis, et al, eds. Springer, 2012.
3. J. van Ingen & P.D.O. Davies. Chapter 6.26; Disease caused by environmental mycobacteria. Oxford Textbook of Medicine, 5th edition. 2012.

Curriculum Vitae Jakko van Ingen

4. J. van Ingen, D. E. Griffith, T. Aksmit, D. Wagner. European Respiratory Monograph: Tuberculosis. 2012
5. J. van Ingen & D. van Soolingen. NTM infections. Nelson's textbook of pediatrics, 20th Edition. 2013.
6. J. van Ingen. Nontuberculous Mycobacteria. In Davies, PDO (ed): Clinical Tuberculosis. 2013.
7. J. van Ingen, C. M. Perez-Velez, S. H. Kasperbauer. Scotochromogenic Mycobacteria. In Yu VL, Weber R, Raoult D (Eds): Antimicrobial Therapy & Vaccines. 2016.
8. J. van Ingen. Nontuberculous mycobacteria. In Cohen J & Powderly WG & Opal SM (Eds): Infectious Diseases, 4th Edition, 2016.
9. J. van Ingen. Diagnosis of mycobacterial diseases. In Cohen J & Powderly WG & Opal SM (Eds): Infectious Diseases, 4th Edition, 2016.
10. J. van Ingen. Clarithromycin. In Kucer's 7th Edition, 2017.

Webinars:

1. European Respiratory Society online course Nontuberculous Mycobacterial disease. Management of nontuberculous mycobacterial disease. 07/2015
2. Henry Stewart Talks, Respiratory Infection series. Diagnosis and management of non-tuberculous mycobacterial pulmonary disease. 09/2015